Understanding Chronic Lymphocytic Leukemia
Leukemia is a type of cancer that originates in blood-producing organs, such as the bone marrow, and causes the uncontrolled proliferation of white blood cells. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults in Western countries. This learning program is designed to introduce you to the main clinical features of CLL. The program begins with a brief overview of the classification of CLL, including a presentation of the hierarchy of lymphomas and the subtypes of CLL. You will then learn about the tools used to establish diagnosis and determine prognosis for CLL. You will also learn about the clinical management of CLL. As you progress through the program, you will also follow the case of Richard Ellis, a 71-year-old man suffering from CLL.
Upon completion of this learning program, you will be able to::
- Define CLL and identify its 2 disease subtypes.
- Describe the general epidemiology trends and risk factors for CLL.
- Explain the tools used to establish diagnosis and determine prognosis for CLL.
- Discuss the clinical management of CLL.
- Hand icon: Hodgkin lymphoma
- Hand icon: Non-Hodgkin lymphoma
- Side note: Digging deeper
- Popup: Somatic hypermutation
- Animated popup: CLL disease mechanism (Narrated)
- Hand icon: IgV-unmutated CLL
- Hand icon: IgV-mutated CLL
- Popup: 13q deletion
- Popup: 11q deletion
- Popup: 17p deletion
- Popup: Additional chromosome
- Popup: Age, gender, and race
- Popup: Family history and genetic predisposition
- Popup: Clinical manifestation of other diseases
- Side note: Digging deeper
- Popup: CLL cells under the microscope
- Popup: Differential diagnosis with flow cytometry
- Hand Icon: Bone marrow aspiration
- Hand Icon: Bone marrow biopsy
- Popup: Rai system
- Popup: Binet system
- Popup: IgV mutational status
- Popup: CD38 immunophenotype
- Popup: ZAP-70 expression
- Popup: Chromosomal abnormalities
- Popup: Levels of serum β-2 microglobulin and lymphocyte doubling time
- Hand Icon: Risk of infection
- Hand Icon: Autoimmunity
- Hand Icon: Transformation
- Hand Icon: Secondary malignancies
- Popup: Alkylating agents
- Popup: Purine nucleoside analogs
- Popup: Bifunctional agents
- Popup: Fludarabine, cyclophosphamide, and rituximab
- Popup: Fludarabine and rituximab
- Popup: Pentostatin, cyclophosphamide, and rituximab
- Popup: Bendamustine and rituximab
- Popup: Relapsed and refractory patients
- Popup: Additional cytogenetic abnormalities
Accepts: 
